Janus Henderson Group PLC Buys New Holdings in Clovis Oncology, Inc. (NASDAQ:CLVS)

Janus Henderson Group PLC acquired a new stake in Clovis Oncology, Inc. (NASDAQ:CLVS) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 217,205 shares of the biopharmaceutical company’s stock, valued at approximately $20,337,000. Janus Henderson Group PLC owned 0.44% of Clovis Oncology at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Advisors Asset Management Inc. grew its stake in Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the period. Legato Capital Management LLC bought a new position in Clovis Oncology in the 2nd quarter valued at $220,000. Bank of Montreal Can grew its stake in Clovis Oncology by 284.9% in the 2nd quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 2,000 shares during the period. Stevens Capital Management LP bought a new position in Clovis Oncology in the 2nd quarter valued at $257,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Clovis Oncology by 3.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Shares of Clovis Oncology, Inc. (NASDAQ CLVS) traded up 3.55% during midday trading on Friday, hitting $76.99. The stock had a trading volume of 1,705,716 shares. The company’s 50 day moving average is $77.56 and its 200 day moving average is $72.03. Clovis Oncology, Inc. has a 52-week low of $25.81 and a 52-week high of $99.45. The company’s market cap is $3.76 billion.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million during the quarter, compared to the consensus estimate of $13.07 million. Clovis Oncology’s revenue was down 32.5% compared to the same quarter last year. During the same period last year, the business earned ($2.07) EPS. On average, analysts anticipate that Clovis Oncology, Inc. will post ($7.58) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/217205-shares-in-clovis-oncology-inc-clvs-purchased-by-janus-henderson-group-plc.html.

Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research note on Tuesday, October 17th. Leerink Swann cut their price target on Clovis Oncology to $107.00 and set an “outperform” rating for the company in a research note on Friday, August 18th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Barclays PLC assumed coverage on Clovis Oncology in a report on Monday, October 23rd. They set an “overweight” rating and a $105.00 price objective on the stock. Finally, BidaskClub cut Clovis Oncology from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 9th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $87.56.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $69.50, for a total value of $208,500.00. Following the completion of the transaction, the insider now owns 191,583 shares in the company, valued at approximately $13,315,018.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James C. Blair sold 18,450 shares of Clovis Oncology stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $78.61, for a total value of $1,450,354.50. Following the transaction, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The disclosure for this sale can be found here. Insiders sold a total of 27,450 shares of company stock valued at $2,122,625 in the last 90 days. 12.50% of the stock is currently owned by company insiders.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply